

RECEIVED

JUL 17 2003

TECH CENTER 1600/2900 Atty Docket: 010969



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

623  
# 16  
NW  
7/22/02

In re the Application of: Masatoshi NODA et al.

Serial Number: 09/926,005

Group Art Unit: 1623

Filed: November 2, 2001

Examiner: Ganapathy KRISHNAN

For: ADP-RIBOSYLATION INHIBITOR COMPRISING PROANTHOCYANIDIN AS AN  
ACTIVE INGREDIENT AND A COMPOSITION FOR TREATING ENTEROTOXIN  
TYPE BACTERIAL INFECTIOUS DISEASE

**INFORMATION DISCLOSURE STATEMENT, PETITION, CERTIFICATION  
AND TRANSMITTAL OF FEE PURSUANT TO 37 CFR 1.97(d)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Attn: Group Director

Date: July 14, 2003

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. One copy of each of these documents is attached.

Petition is hereby made for consideration of this Information Disclosure Statement, which is being submitted after issuance of either a final official action or a Notice of Allowance, but on or before payment of the Issue Fee.

The undersigned hereby certifies

XX that each item of information contained in this statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement, or

\_ that no item of information contained in this statement was cited in a communication from

a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, no information contained in this statement was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this statement.

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO-1449 be made of record therein and appear on the first page of any patent to issue therefrom.

A check is attached hereto which covers the \$ 180.00 fee set forth in 37 CFR § 1.17(p). The Commissioner is hereby authorized to charge any additional fee (or credit any overpayment) associated with this Statement to our Deposit Account No. 01-2340.

Respectfully submitted,

ARMSTRONG, WESTERMAN & HATTORI, LLP




Nicolas E. Seckel

Attorney for Applicant(s)

Reg. No. 44,373

Atty. Docket No. **010969**  
1725 K Street, N.W., Suite 1000  
Washington, DC 20006  
Tel: (202) 659-2930  
Fax: (202) 887-0357  
NES/ya

Encls: PTO-1449  
Supplementary European Search Report and 5 References



<b>INFORMATION DISCLOSURE CITATION PTO-1449</b>	Atty. Docket No. <b>010969</b>	Serial No. <b>09/926,005</b>
	Applicant(s): <b>Masatoshi NODA et al.</b>	
	Filing Date: <b>November 2, 2001</b>	Group Art Unit: <b>1623</b>

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document No.	Name	Date	Class	Subclass	Filing Date (If appropriate)
_____	AA					
_____	AB					
_____	AC					
_____	AD					
_____	AE					

**FOREIGN PATENT DOCUMENTS**

Document No.	Date	Country	Translation (Yes or No)
_____ AF WO 99 12541	03/18/1999	PCT	N/A
_____ AG WO 98 16111	04/23/1998	PCT	N/A
_____ AH EP 0 606 497	07/20/1994	Europe	N/A
_____ AI			
_____ AJ			

**OTHER DOCUMENTS**

_____	AK	Galvez J. et al. "Antidiarrhoeic Activity of Sclerocarya birrea Bark Extract and its Active Tannin Constituent in Rats", <i>PHYTOTHERAPY RESEARCH</i> , United Kingdom, Vol. 5, No. 6, 1991, pages 276-279
_____	AL	Hoer M. et al. "Inhibition of Intestinal Chloride Secretion by Proanthocyanidins from <i>Guazuma ulmifolia</i> ", <i>PLANTA MEDICA</i> , Vol. 61, No. 3, 1995, pages 208-212
Examiner		Date Considered